中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

184 records (took 0.018 seconds)

    HUMAN INKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
    32.
    发明专利
    HUMAN INKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS 未知

    公开(公告)号：CA2923579A1

    公开(公告)日：2015-03-12

    申请号：CA2923579

    申请日：2014-09-08

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  YU ALICE L ,  LIN KUN-HSIEN ,  WU TAI-NA

    IPC: A61K39/39 ,  A61P35/00 ,  A61P37/04

    Abstract: Glycosphingolipids (GSLs) bearing a-glucose (a-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with a-glucose (a-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with a-galactose (a-Gal) are disclosed. GSLs bearing a-glucose (a-Glc) and derivatives of a-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with a-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with a-Glc and derivatives thereof are provided.

    Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
    33.
    发明专利
    Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados 未知

    公开(公告)号：ES2442024T3

    公开(公告)日：2014-02-07

    申请号：ES09798721

    申请日：2009-07-15

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSENG SUSAN Y

    IPC: C40B40/12 ,  C40B50/14

    Abstract: Una matriz de carbohidratos inmovilizados en un sustrato sólido no transparente revestido con aluminio o unsustrato sólido no transparente revestido con aluminio polifluorado (de tipo politetrafluoroetileno (PTFE)),comprendiendo la matriz: una pluralidad de carbohidratos inmovilizados en localizaciones específicas en una superficie del sustrato sólidono transparente revestido con aluminio, de modo que: (a) los carbohidratos inmovilizados pueden caracterizarse por espectroscopia de masas (EM) y (b) puede realizarse análisis de reacciones de unión entre los carbohidratos y moléculas que se sospechaque se unen específicamente con los carbohidratos, donde el aluminio se usa para revestir un primer sustrato sólido transparente a un grosor mayor de 100 nm paraconvertir el primer sustrato sólido transparente en un sustrato sólido no transparente revestido con aluminio o unsustrato sólido no transparente revestido con aluminio de tipo PTFE polifluorado y donde la superficie del revestimiento de aluminio en el sustrato sólido se anodiza para formar una capa de óxidode aluminio porosa de un grosor menor de 5 nm.

    ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES,ADJUVANTS,AND INTIVIRAL,ANTIBACTERIAL,AND ANTICANCER AGENTS
    34.
    发明专利
    ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES,ADJUVANTS,AND INTIVIRAL,ANTIBACTERIAL,AND ANTICANCER AGENTS 未知

    公开(公告)号：ZA201101128B

    公开(公告)日：2013-11-27

    申请号：ZA201101128

    申请日：2011-02-11

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN ,  LIN KUN-HSIEN ,  HUNG JUNG-TUNG

    IPC: A61K20060101 ,  A61P20060101

    Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.

    Compositions and methods for identifying response targets and treating flavivirus infection responses
    37.
    发明专利
    Compositions and methods for identifying response targets and treating flavivirus infection responses 未知

    公开(公告)号：AU2008353452A1

    公开(公告)日：2009-10-01

    申请号：AU2008353452

    申请日：2008-05-29

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  HSIEH SHIE-LIANG ,  CHEN SZU-TING ,  HSU TSUI-LING

    IPC: G01N33/53

    Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-alpha is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-alpha secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

    Pharmaceutical composition comprising an antibody against cellular receptors involved in pathogen infection
    38.
    发明专利
    Pharmaceutical composition comprising an antibody against cellular receptors involved in pathogen infection 未知

    公开(公告)号：GB2458715A

    公开(公告)日：2009-09-30

    申请号：GB0812915

    申请日：2008-07-15

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  HSIEH SHIE-LIANG ,  HSU TSUI-LING ,  CHEN SZU-TING

    IPC: A61K39/395 ,  C07K16/28

    Abstract: A pharmaceutical composition is disclosed comprising an effective amount of an antibody directed against at least one cellular receptor to modulate the effects of a pathogen infection, wherein the modulation comprises at least inhibition of pro-inflammatory cytokine secretion and does not affect secretion of cytokines that affect viral clearance. The cellular receptor may be the DLVR1 / CLEC5A (DVLR1, MDL-1) receptor. The pathogen may be a hepatitis virus or a flavivirus (e.g. Japanese encephalomyelitis virus or dengue virus). Use of an anti-DLVR1/CLEC5A antibody in the treatment of a flavivirus infection is claimed. A method comprising obtaining a fusion protein comprising a binding domain of a DLVR1/CLEC5A receptor and a domain that allows affixing to a substrate, contacting the fusion protein with a flavivirus to determine if the pathogen binds to the binding domain of the fusion, and detecting whether the pathogen is bound to the fusion protein, is also claimed.

Patent Agency Ranking